BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets

StreetInsider2023-07-29

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2355589586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-07-29 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2355589586","market":"us","top_or_hot":-1,"title":"BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets","media":"StreetInsider","content":"<div>\n<p>BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=21964033\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-07-29 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=21964033><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=21964033\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4114","symbol_name":"综合货品商店","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=21964033","article_id":"2355589586","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2355589586","pubTimestamp":1690563600,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"BiondVax  is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody  therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine, which is implicated in several diseases] for the treatment of psoriasis, where the market for therapeutics is expected to reach $44 billion by 2031,” reads a recent article. “The company’s plan for the IL-17 nanobody also includes addressing diseases like hidradenitis suppurativa , psoriatic arthritis and other large markets. BiondVax intends to use IL-17 in mild-to-moderate psoriasis patients, which comprise a higher number of patients compared to the smaller segment of severe patien","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4114":"综合货品商店","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","TGT":"塔吉特","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK4585":"ETF&股票定投概念","BK4155":"大卖场与超市","BK4007":"制药","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4504":"桥水持仓","LU0823411888.USD":"法巴消费创新基金 Cap","BK4588":"碎股","BK4532":"文艺复兴科技持仓"},"translate_title":"BiomedNewsBreaks-BiondVax Pharmaceuticals Ltd.（纳斯达克：BVXV）利用独特的NanoAb管道瞄准不断增长的大市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGT":1,"BVXV":1},"content_text":"BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine, which is implicated in several diseases] for the treatment of psoriasis, where the market for therapeutics is expected to reach $44 billion by 2031,” reads a recent article. “The company’s plan for the IL-17 nanobody also includes addressing diseases like hidradenitis suppurativa (‘HS’), psoriatic arthritis and other large markets. BiondVax intends to use IL-17 in mild-to-moderate psoriasis patients, which comprise a higher number of patients compared to the smaller segment of severe patients [targeted in a previous competitor trial].”\nTo view the full article, visit https://ibn.fm/BmIqW\nAbout BiondVax Pharmaceuticals Ltd.\nBiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.\nNOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV\nAbout BioMedWire\nBioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.\nTo receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)\nFor more information please visit https://www.biomedwire.com\nPlease see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer\nBioMedWire (BMW)San Francisco, Californiawww.biomedwire.com415.949.5050 Office[email protected]\nBioMedWire is part of the InvestorBrandNetwork","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2355589586"}